Emilia Scalzulli Selected Research

Leukemia

6/2022	Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
1/2021	Therapeutic strategies in low and high-risk MDS: What does the future have to offer?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emilia Scalzulli Research Topics

Disease

32	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2024 - 12/2017
6	Primary Myelofibrosis (Myelosclerosis) 02/2024 - 08/2019
6	Neoplasms (Cancer) 02/2024 - 08/2019
3	Polycythemia Vera 01/2023 - 10/2020
3	Splenomegaly 01/2023 - 08/2019
3	Anemia 01/2021 - 01/2019
2	Myeloid Leukemia (Leukemia, Myelocytic) 01/2023 - 12/2020
2	Hypertension (High Blood Pressure) 01/2023 - 07/2020
2	Leukemia 06/2022 - 01/2021
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 08/2019
1	Inflammation (Inflammations) 02/2024
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2023
1	Carcinoma (Carcinomatosis) 01/2023
1	Hematologic Diseases (Blood Diseases) 01/2023
1	Infections 01/2023
1	Melanoma (Melanoma, Malignant) 01/2023
1	Skin Neoplasms (Skin Cancer) 01/2023
1	Thrombocytosis (Thrombocythemia) 01/2023
1	Merkel Cell Carcinoma 01/2023
1	Abdominal Pain (Pain, Abdominal) 01/2023
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2023
1	Stroke (Strokes) 01/2023
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2023
1	Disease Progression 11/2022
1	Residual Neoplasm 01/2022
1	Dyslipidemias (Dyslipidemia) 08/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Hydrocephalus (Hydrocephaly) 01/2021
1	Atrial Fibrillation 12/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2020
1	Multiple Myeloma 01/2018

Drug/Important Bio-Agent (IBA)

21	Tyrosine Kinase InhibitorsIBA 02/2024 - 12/2017
8	ruxolitinibIBA 02/2024 - 08/2019
7	Imatinib Mesylate (Gleevec)FDA Link 09/2023 - 01/2019
6	nilotinib FDA Link 11/2023 - 01/2019
6	ponatinibIBA 11/2023 - 01/2019
3	asciminibIBA 01/2023 - 08/2021
3	Dasatinib (BMS 354825)FDA Link 01/2023 - 01/2019
2	LDL Lipoproteins (beta Lipoproteins)IBA 08/2021 - 01/2020
2	Phosphotransferases (Kinase)IBA 12/2020 - 08/2019
2	AnticoagulantsIBA 12/2020 - 12/2020
2	Azacitidine (5 Azacytidine)FDA Link 10/2020 - 08/2019
2	Erythropoietin FDA Link 09/2020 - 01/2019
1	Biomarkers (Surrogate Marker)IBA 02/2024
1	avelumabIBA 01/2023
1	Hemoglobins (Hemoglobin)IBA 01/2023
1	Lamivudine (Epivir)FDA Link 01/2023
1	Lenalidomide (CC 5013)FDA Link 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2021
1	cemiplimabIBA 08/2021
1	oxidized low density lipoproteinIBA 08/2021
1	InterferonsIBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2021
1	CytokinesIBA 10/2020
1	Decitabine FDA Link 10/2020
1	Angiotensin Receptor AntagonistsIBA 07/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 07/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	LDL CholesterolIBA 01/2020
1	Hydroxyurea (Hydrea)FDA LinkGeneric 08/2019
1	bosutinibIBA 01/2019
1	Proteasome InhibitorsIBA 01/2018

Therapy/Procedure

6	Therapeutics 09/2023 - 01/2018
1	Immunotherapy 01/2023
1	Secondary Prevention 01/2019